The Role of Lapatinib in the Preoperative Therapy of Breast Cancer

被引:0
作者
Hirsh, Rebecca L. [1 ,2 ]
DeMichele, Angela [1 ,2 ,3 ]
机构
[1] Univ Penn, Dept Med, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
Neoadjuvant; HER2; Lapatinib; Trastuzumab; Breast cancer; PATHOLOGICAL COMPLETE RESPONSE; PHASE-II TRIAL; NEOADJUVANT THERAPY; ADJUVANT CHEMOTHERAPY; STAGE-II; TRASTUZUMAB; PLUS; DOCETAXEL; PACLITAXEL;
D O I
10.1007/s11912-011-0206-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Preoperative or neoadjuvant chemotherapy is a well-established modality in the treatment of nonmetastatic breast cancer. Patients initially considered inoperable may be able to achieve operable status after preoperative chemotherapy and patients initially considered not to be candidates for breast conservation may convert to breast conservation status. Human epidermal growth factor receptor 2 (Her2)-positive tumors have been shown to have a more aggressive course including early local relapse and metastasis when compared to Her2-negative breast cancers, but the optimal use of Her2-targeted agents is constantly evolving as new agents become available. Preoperative studies allow us to quickly assess the activity of new agents and combinations for particular biological subsets of breast cancer.
引用
收藏
页码:44 / 47
页数:4
相关论文
共 50 条
  • [31] Preoperative treatment of HER2-positive breast cancer
    Wysocki, Piotr J.
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (02): : 69 - 74
  • [32] The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
    Chen, Zhe-Ling
    Shen, Yan-Wei
    Li, Shu-Ting
    Li, Chun-Li
    Zhang, Ling-Xiao
    Yang, Jiao
    Lv, Meng
    Lin, Ya-Yun
    Wang, Xin
    Yang, Jin
    ONCOTARGETS AND THERAPY, 2016, 9 : 3233 - 3247
  • [33] Local and regional therapy considerations after preoperative therapy in patients with breast cancer
    Untch, Michael
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2021, 33 (01) : 59 - 63
  • [34] Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
    Cameron, David
    Casey, Michelle
    Oliva, Cristina
    Newstat, Beth
    Imwalle, Bradley
    Geyer, Charles E.
    ONCOLOGIST, 2010, 15 (09) : 924 - 934
  • [35] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Rugo, Hope S.
    Chien, A. Jo
    Franco, Sandra X.
    Stopeck, Alison T.
    Glencer, Alexa
    Lahiri, Soumi
    Arbushites, Michael C.
    Scott, Janet
    Park, John W.
    Hudis, Clifford
    Nulsen, Ben
    Dickler, Maura N.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 13 - 20
  • [36] Metastatic Breast Cancer: The Individualization of Therapy
    Mahon, Suzanne M.
    Palmieri, Frances M.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2009, 13 (01) : 19 - 28
  • [37] Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
    Yardley, Denise A.
    Hart, Lowell
    Bosserman, Linda
    Salleh, Mansoor N.
    Waterhouse, David M.
    Hagan, Maura K.
    Richards, Paul
    DeSilvio, Michelle L.
    Mahoney, Janine M.
    Nagarwala, Yasir
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 457 - 464
  • [38] Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy
    Ebinc, Senar
    Oruc, Zeynep
    Sezgin, Yasin
    Karhan, Ogur
    Bilen, Erkan
    Yerlikaya, Halis
    Kalkan, Ziya
    Urakci, Zuhat
    Kucukoner, Mehmet
    Kaplan, Muhammet Ali
    Isikdogan, Abdurrahman
    FUTURE ONCOLOGY, 2022, 18 (30) : 3399 - 3408
  • [39] Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+metastatic breast cancer
    Wu, Y.
    Amonkar, M. M.
    Sherrill, B. H.
    O'Shaughnessy, J.
    Ellis, C.
    Baselga, J.
    Blackwell, K. L.
    Burstein, H. J.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2582 - 2590
  • [40] Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment
    Zhou, Xiaolei
    Cella, David
    Cameron, David
    Amonkar, Mayur M.
    Segreti, Anthony
    Stein, Steven
    Walker, Mel
    Geyer, Charles E.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (03) : 577 - 589